Latest Period
Q1 2026
Security Snapshot
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) Institutional Ownership
CUSIP: 52886X107
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
137
Shares (Excl. Options)
79,828,179
Price
$5.74
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- LXEO on Nasdaq
- Shares outstanding
- 74,507,639
- Reported price per share
- $5.74
- Price from insider filings
- $5.74
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 79,828,179
- Total reported value
- $458,111,283
- Portfolio coverage rank
- 0%
- Share change
- +3,328,129
- Value change
- +$6,784,679
- Number of holders
- 137
Security identity
Issuer context
Latest holder snapshot
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- LXEO - Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 52886X107.
- 137 institutions reported positions in Q1 2026.
- 17 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 146 to 137 between Q4 2025 and Q1 2026.
- Reported value moved from $759,235,996 to $458,111,283.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 137 institutions filings for Q1 2026.
Security key
52886X107
Latest holder period
Q1 2026
13F holders
137
13D/G owners
17
CIK / CUSIP context first
Open Q1 2026 holders
LXEO full holder history
Lexeo Therapeutics, Inc. SEC filings
Lexeo Therapeutics, Inc. company facts
Lexeo Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 52886X107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
17
Security
LXEO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% | -12% | $65,914,563 | +$10,720,599 | 7,291,434 | +19% | JANUS HENDERSON GROUP PLC | 28 Nov 2025 |
| BALYASNY ASSET MANAGEMENT L.P. | 9.7% | -2% | $41,191,067 | -$260,659 | 7,176,144 | -0.63% | Balyasny Asset Management L.P. | 31 Mar 2026 |
| Paradigm Biocapital Advisors LP | 8.3% | +26% | $35,496,929 | +$8,156,173 | 6,184,134 | +30% | Paradigm BioCapital Advisors LP | 31 Mar 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.7% | $32,573,226 | 5,674,778 | SUVRETTA CAPITAL MANAGEMENT, LLC | 06 Apr 2026 | |||
| CITADEL ADVISORS LLC | 7.4% | -22% | $40,851,767 | +$1,219,315 | 5,498,219 | +3.1% | Kenneth Griffin | 31 Dec 2025 |
| Affinity Asset Advisors, LLC | 7.1% | -8.1% | $51,813,451 | +$9,589,340 | 5,217,660 | +23% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 6.9% | $33,200,000 | 5,000,000 | RA Capital Management, L.P. | 20 Oct 2025 | |||
| BlackRock, Inc. | 6.7% | +68% | $48,518,087 | +$26,984,571 | 4,885,814 | +125% | BlackRock, Inc. | 31 Dec 2025 |
| Vestal Point Capital, LP | 7.5% | +25% | $27,338,885 | +$5,903,896 | 4,117,302 | +28% | Vestal Point Capital, LP | 30 Sep 2025 |
| Frazier Life Sciences Public Fund, L.P. | 5.1% | -10% | $27,478,154 | +$4,642,294 | 3,698,271 | +20% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| Longitude Capital Partners IV, LLC | 3.8% | $18,362,130 | 2,765,381 | Longitude Capital Partners IV, LLC | 30 Sep 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 3.2% | -42% | $15,362,583 | -$3,470,396 | 2,313,642 | -18% | Millennium Management LLC | 30 Sep 2025 |
| MIZUHO FINANCIAL GROUP INC | 6.6% | +13% | $8,109,362 | +$1,020,464 | 2,203,631 | +14% | Mizuho Financial Group, Inc. | 31 Mar 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.7% | $4,544,189 | 1,234,834 | Eventide Asset Management, LLC | 31 Dec 2024 | |||
| Omega Fund VI, L.P. | 3.6% | $4,359,460 | 1,184,636 | Omega Fund VI, L.P. | 31 Dec 2024 | |||
| D1 Capital Partners L.P. | 2.9% | $3,601,439 | 978,652 | D1 Capital Partners L.P. | 31 Mar 2025 | |||
| Adage Capital Management, L.P. | 0.7% | -85% | $875,667 | -$7,255,716 | 237,953 | -89% | Adage Capital Management, L.P. | 31 Mar 2025 |
As of 31 Mar 2026, 137 institutional investors reported holding 79,828,179 shares of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO). This represents 107% of the company’s total 74,507,639 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
95%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 8.3% | 6,184,134 | +30% | 0.73% | $35,496,929 |
| BlackRock, Inc. | 6.9% | 5,110,871 | +4.1% | 0% | $29,336,401 |
| Affinity Asset Advisors, LLC | 6.8% | 5,050,211 | +58% | 1.7% | $28,988,211 |
| RA CAPITAL MANAGEMENT, L.P. | 6.7% | 5,000,000 | 0% | 0.3% | $28,700,000 |
| JANUS HENDERSON GROUP PLC | 6.7% | 4,976,429 | -9.7% | 0.01% | $28,510,358 |
| Vestal Point Capital, LP | 6% | 4,475,000 | 0% | 0.72% | $25,686,500 |
| Frazier Life Sciences Management, L.P. | 5.9% | 4,424,725 | 0% | 0.65% | $25,397,922 |
| CITADEL ADVISORS LLC | 5.1% | 3,834,999 | +1.6% | 0.02% | $22,012,895 |
| ORBIMED ADVISORS LLC | 4.8% | 3,602,450 | +70% | 0.47% | $20,678,063 |
| STATE STREET CORP | 4.8% | 3,568,242 | +12% | 0% | $20,481,709 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 3,007,093 | 0% | 0% | $17,260,714 |
| Woodline Partners LP | 3.7% | 2,750,532 | -14% | 0.06% | $15,788,054 |
| GOLDMAN SACHS GROUP INC | 2.6% | 1,949,885 | +149% | 0% | $11,192,340 |
| Avoro Capital Advisors LLC | 2.5% | 1,875,000 | -43% | 0.11% | $10,762,500 |
| Point72 Asset Management, L.P. | 2.3% | 1,680,449 | -11% | 0.02% | $9,645,777 |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 1,612,780 | +78% | 0.01% | $9,257,357 |
| Balyasny Asset Management L.P. | 2.1% | 1,589,585 | -2.8% | 0.02% | $9,124,218 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,513,777 | +4.7% | 0% | $8,691,154 |
| ADAR1 Capital Management, LLC | 2% | 1,467,350 | +5.3% | 0.51% | $8,422,589 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1.7% | 1,250,000 | 0% | 0.19% | $7,175,000 |
| 683 Capital Management, LLC | 1.6% | 1,200,000 | +7.1% | 0.64% | $6,888,000 |
| Nantahala Capital Management, LLC | 1.6% | 1,200,000 | +20% | 0.43% | $6,888,000 |
| DIMENSIONAL FUND ADVISORS LP | 1.5% | 1,103,584 | +28% | 0% | $6,331,850 |
| Octagon Capital Advisors LP | 1.5% | 1,100,000 | -36% | 0.7% | $6,314,000 |
| Spruce Street Capital LP | 1.2% | 928,593 | +431% | 1.3% | $5,330,124 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 79,828,179 | $458,111,283 | +$6,784,679 | $5.74 | 137 |
| 2025 Q4 | 76,464,823 | $759,235,996 | +$269,440,399 | $9.93 | 146 |
| 2025 Q3 | 49,322,779 | $327,479,655 | +$52,645,662 | $6.64 | 108 |
| 2025 Q2 | 42,272,843 | $169,997,165 | +$59,022,508 | $4.02 | 90 |
| 2025 Q1 | 28,007,948 | $99,996,757 | -$11,520,766 | $3.47 | 88 |
| 2024 Q4 | 29,519,159 | $194,192,987 | -$4,086,062 | $6.58 | 89 |
| 2024 Q3 | 29,735,114 | $268,784,046 | +$10,322,355 | $9.04 | 67 |
| 2024 Q2 | 26,566,622 | $426,105,401 | +$55,254,655 | $16.04 | 57 |
| 2024 Q1 | 23,119,889 | $361,545,010 | +$108,427,159 | $15.68 | 54 |
| 2023 Q4 | 16,174,480 | $217,090,546 | +$217,090,546 | $13.42 | 31 |